Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00721513 · OUTCOME

Objective Response Rate

Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer · Source last updated 2020-04-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
up to 2 years

What was measured

Will be measured by CT scan /MRI of the head and neck with corroborative results of direct biopsy of any residual tumor at primary site.

Groups in this outcome

TPFChemotherapy + Concomitant Cetuximab & RT

Taxotere/Cisplatinum/5-Fluorouracil (TPF) Chemotherapy Followed by Concomitant Cetuximab \& Radiation Therapy cetuximab cisplatin docetaxel fluorouracil computed tomography positron emission tomography quality-of-life assessment 3-dimensional conformal radiation therapy intensity-modulated radiation therapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
TPFChemotherapy + Concomitant Cetuximab & RT20

Reported measurements

Source class 1

Complete response

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
TPFChemotherapy + Concomitant Cetuximab & RT5Not reportedNot reportedNot reportedNot reported

Partial response

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
TPFChemotherapy + Concomitant Cetuximab & RT10Not reportedNot reportedNot reportedNot reported

Stable disease

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
TPFChemotherapy + Concomitant Cetuximab & RT1Not reportedNot reportedNot reportedNot reported

Progression of disease

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
TPFChemotherapy + Concomitant Cetuximab & RT4Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        5
      title
      Complete response
    2. measurements
      1. group Id
        OG000
        value
        10
      title
      Partial response
    3. measurements
      1. group Id
        OG000
        value
        1
      title
      Stable disease
    4. measurements
      1. group Id
        OG000
        value
        4
      title
      Progression of disease
denoms
  1. counts
    1. group Id
      OG000
      value
      20
    units
    Participants
description
Will be measured by CT scan /MRI of the head and neck with corroborative results of direct biopsy of any residual tumor at primary site.
groups
  1. description
    Taxotere/Cisplatinum/5-Fluorouracil (TPF) Chemotherapy Followed by Concomitant Cetuximab \& Radiation Therapy cetuximab cisplatin docetaxel fluorouracil computed tomography positron emission tomography quality-of-life assessment 3-dimensional conformal radiation therapy intensity-modulated radiation therapy
    id
    OG000
    title
    TPFChemotherapy + Concomitant Cetuximab & RT
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
up to 2 years
title
Objective Response Rate
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice